×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CABA – cabaletta bio, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CABA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/18
05:41 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "outperform" rating re-affirmed by analysts at William Blair.
11/18
07:12 am
caba
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 [Yahoo! Finance]
High
Report
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 [Yahoo! Finance]
11/18
07:00 am
caba
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
High
Report
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
11/15
03:26 pm
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $12.00. They now have an "overweight" rating on the stock.
Low
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $12.00. They now have an "overweight" rating on the stock.
11/15
08:03 am
caba
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
High
Report
Cabaletta Bio, Inc. (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
11/14
07:09 am
caba
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
11/14
07:00 am
caba
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
08:00 am
caba
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Medium
Report
Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/18
07:06 am
caba
Form 8-K Cabaletta Bio, Inc. For: Nov 18
High
Report
Form 8-K Cabaletta Bio, Inc. For: Nov 18
11/14
05:47 pm
caba
Form SC 13G/A Cabaletta Bio, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.
High
Report
Form SC 13G/A Cabaletta Bio, Inc. Filed by: Venrock Healthcare Capital Partners III, L.P.
11/14
04:04 pm
caba
Form SC 13G/A Cabaletta Bio, Inc. Filed by: ALGER ASSOCIATES INC
High
Report
Form SC 13G/A Cabaletta Bio, Inc. Filed by: ALGER ASSOCIATES INC
11/14
01:30 pm
caba
Form SC 13G Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.
Low
Report
Form SC 13G Cabaletta Bio, Inc. Filed by: T. Rowe Price Investment Management, Inc.
11/14
07:14 am
caba
Form 10-Q Cabaletta Bio, Inc. For: Sep 30
Medium
Report
Form 10-Q Cabaletta Bio, Inc. For: Sep 30
11/14
07:07 am
caba
Form 8-K Cabaletta Bio, Inc. For: Nov 14
Medium
Report
Form 8-K Cabaletta Bio, Inc. For: Nov 14
11/12
01:25 pm
caba
Form SC 13G/A Cabaletta Bio, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Cabaletta Bio, Inc. Filed by: VANGUARD GROUP INC
11/12
09:39 am
caba
Form SC 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.
Low
Report
Form SC 13G/A Cabaletta Bio, Inc. Filed by: Adage Capital Management, L.P.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
11/19
Cabaletta Bio (NASDAQ: CABA) had its "buy" rating re-affirmed by analysts at Cowen Inc.
28.4%
2/14 Form SC 13G/A Cabaletta Bio, Inc. Filed by: Cormorant Asset Management, LP 17.0%
1/29 Form 8-K Cabaletta Bio, Inc. For: Jan 29 13.4%
10/24 Form S-1MEF Cabaletta Bio, Inc. 11.1%
3/3 Form 4 Cabaletta Bio, Inc. For: Mar 01 Filed by: Marda Anup 5.9%
3/30 Form 10-K Cabaletta Bio, Inc. For: Dec 31 4.0%
10/28 Form 4 Cabaletta Bio, Inc. For: Oct 24 Filed by: Chang David J. 2.5%
4/16 Cabaletta Bio (NASDAQ: CABA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.4%
10/31 Form 4 Cabaletta Bio, Inc. For: Oct 29 Filed by: 5AM Partners V, LLC 2.4%
2/13 Form SC 13G/A Cabaletta Bio, Inc. Filed by: Flynn James E 1.5%
2/14 Form SC 13G/A Cabaletta Bio, Inc. Filed by: Cormorant Asset Management, LP 17.0%
1/29 Form 8-K Cabaletta Bio, Inc. For: Jan 29 13.4%
10/24 Form S-1MEF Cabaletta Bio, Inc. 11.1%
3/3 Form 4 Cabaletta Bio, Inc. For: Mar 01 Filed by: Marda Anup 5.9%
3/30 Form 10-K Cabaletta Bio, Inc. For: Dec 31 4.0%
10/28 Form 4 Cabaletta Bio, Inc. For: Oct 24 Filed by: Chang David J. 2.5%
4/16 Cabaletta Bio (NASDAQ: CABA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 2.4%
10/31 Form 4 Cabaletta Bio, Inc. For: Oct 29 Filed by: 5AM Partners V, LLC 2.4%
2/13 Form SC 13G/A Cabaletta Bio, Inc. Filed by: Flynn James E 1.5%
TOP News Decliners
12/5
Form 10-Q Cabaletta Bio, Inc. For: Sep 30
-16.0%
11/12 Form SC 13D Cabaletta Bio, Inc. Filed by: 5AM Ventures V, L.P. -12.0%
3/5 Cabaletta Bio (NASDAQ: CABA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.7%
11/22 Form SEC STAFF LETTER Cabaletta Bio, Inc. -4.5%
11/26 Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference -4.5%
1/10 Form 8-K Cabaletta Bio, Inc. For: Jan 10 -4.5%
4/23 Form DEF 14A Cabaletta Bio, Inc. For: Jun 02 -4.4%
4/15 Cabaletta Bio (NASDAQ: CABA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.25 price target on the stock. -3.6%
10/29 Form 4 Cabaletta Bio, Inc. For: Oct 29 Filed by: Green Jeremy -3.2%
2/20 Form 8-K Cabaletta Bio, Inc. For: Feb 20 -3.0%
11/12 Form SC 13D Cabaletta Bio, Inc. Filed by: 5AM Ventures V, L.P. -12.0%
3/5 Cabaletta Bio (NASDAQ: CABA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -5.7%
11/22 Form SEC STAFF LETTER Cabaletta Bio, Inc. -4.5%
11/26 Cabaletta Bio to Present at the Evercore ISI 2nd Annual HealthCONx Conference -4.5%
1/10 Form 8-K Cabaletta Bio, Inc. For: Jan 10 -4.5%
4/23 Form DEF 14A Cabaletta Bio, Inc. For: Jun 02 -4.4%
4/15 Cabaletta Bio (NASDAQ: CABA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $8.25 price target on the stock. -3.6%
10/29 Form 4 Cabaletta Bio, Inc. For: Oct 29 Filed by: Green Jeremy -3.2%
2/20 Form 8-K Cabaletta Bio, Inc. For: Feb 20 -3.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: